{"id":11381,"date":"2024-08-14T10:52:36","date_gmt":"2024-08-14T10:52:36","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/axafa\/"},"modified":"2024-12-16T13:20:36","modified_gmt":"2024-12-16T13:20:36","slug":"axafa","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/axafa\/","title":{"rendered":"AXAFA"},"content":{"rendered":"\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:40%\"><div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"600\" height=\"600\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/07\/axafa_600x600px.jpg\" alt=\"\" class=\"wp-image-712\" style=\"width:337px\" srcset=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/07\/axafa_600x600px.jpg 600w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/07\/axafa_600x600px-300x300.jpg 300w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/07\/axafa_600x600px-150x150.jpg 150w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/figure>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:60%\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-740174f57f8a38415adc287cd355c251\" style=\"text-transform:uppercase\"><strong>AXAFA<\/strong>-AFNET 5<\/h2>\n\n\n\n<div class=\"axafa\"> <\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy (AXAFA)<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" id=\"abstand-weg\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-background\" id=\"studiendesign-block-hacken\" style=\"background-color:#dde9f2\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-66e5c26a43ec417bba9a894e5c30b16c\" style=\"text-transform:uppercase\"><strong>Study design<\/strong><\/h2>\n\n\n\n<div class=\"studydesign-dotted\"> <\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Investigator-driven, prospective, parallel-group, randomised, open, Blinded Outcome Assessment (PROBE),multi-centre trial to determine the optimal anticoagulation therapy for patients undergoing catheter ablation of atrial fibrillation<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" id=\"video-studien-margin-top-less\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-1024x683.jpg\" alt=\"\" class=\"wp-image-6495\" srcset=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-1024x683.jpg 1024w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-300x200.jpg 300w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-768x513.jpg 768w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-1536x1025.jpg 1536w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-2048x1367.jpg 2048w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-500x334.jpg 500w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-800x534.jpg 800w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-1280x854.jpg 1280w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/10\/signing-business-document-1920x1281.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" id=\"positiv-zeichen\">\n<h5 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-05744b5ae8840d59b857e20d2455e3d7\"><strong>Inclusion Criteria<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"17\" height=\"30\" class=\"wp-image-2570\" style=\"width: 17px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2713.png\" alt=\"\"> Non-valvular AF (ECG-documented) with a clinical indication for catheter ablation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"17\" height=\"30\" class=\"wp-image-2570\" style=\"width: 17px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2713.png\" alt=\"\"> Clinical indication to undergo catheter ablation on continuous anticoagulant therapy<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"17\" height=\"30\" class=\"wp-image-2570\" style=\"width: 17px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2713.png\" alt=\"\"> Presence of at least one of the CHADS2 stroke risk factors<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Stroke or TIA<\/li>\n\n\n\n<li><span style=\"color: initial;\">age \u2265 75 years,<\/span><\/li>\n\n\n\n<li><span style=\"color: initial;\">hypertension, defined as chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure &gt; 145\/90 mm Hg,<\/span><\/li>\n\n\n\n<li>diabetes mellitus,<\/li>\n\n\n\n<li>symptomatic heart failure (NYHA \u2265 II).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"17\" height=\"30\" class=\"wp-image-2570\" style=\"width: 17px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2713.png\" alt=\"\"> Age \u2265 18 years<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"17\" height=\"30\" class=\"wp-image-2570\" style=\"width: 17px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2713.png\" alt=\"\"> Provision of signed informed consent<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" id=\"negativ-zeichen\">\n<h5 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-5c6b1628f4524a006124ac6418251f76\"><strong>General exclusion criteria<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Any disease that limits life expectancy to less than 1 year<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Participation in another clinical trial, either within the past two months or still ongoing<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Previous participation in AXAFA<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Pregnant women or women of childbearing potential not on adequate birth control: only women with a highly effective method of contraception (oral contraception or intra-uterine device) or sterile women can be randomised.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Breastfeeding women<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\">Drug abuse or clinically manifest alcohol abuse<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Any stroke within 14 days before randomisation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Coadministration with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) or strong dual inducers of CYP3A4 and P-gp (Appendix VIII).<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" id=\"negativ-zeichen\">\n<h5 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-f1a2157465824ac8907c914b67e80914\"><strong>Exclusion criteria related to a cardiac condition<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Valvular AF (as defined by the focussed update of the ESC guidelines on AF, i.e. severe mitral valve stenosis, mechanical heart valve). Furthermore, patients who underwent mitral valve repair are not eligible for AXAFA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Any previous ablation or surgical therapy for AF<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Cardiac ablation therapy for any indication (catheter-based or surgical) within 3 months prior to randomisation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Clinical need for &#8220;triple therapy&#8221; (combination therapy of clopidogrel, acetylsalicylic acid, and oral anticoagulation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Other contraindications for use of VKA or apixaban<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Documented atrial thrombi less than 3 months prior to randomisation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Exclusion criteria based on laboratory abnormalities<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"19\" height=\"30\" class=\"wp-image-2571\" style=\"width: 19px;\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/\u2717.png\" alt=\"\"> Severe chronic kidney disease with an estimated glomerular filtration rate (GFR) &lt; 15 ml\/min<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-b0997938a1603e9b53dd0a406c1902b0\" style=\"text-transform:uppercase\"><strong><strong>hypothesis<\/strong><\/strong><\/h2>\n\n\n\n<div class=\"research-dotted\"> <\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Anticoagulation with the direct factor Xa inhibitor apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing catheter ablation of non-valvular AF in the prevention of peri-procedural complications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-80931c02f799cf7f592c4cdbd6413e95\" style=\"text-transform:uppercase\"><strong>Conclusion <\/strong><\/h2>\n\n\n\n<div class=\"conclusion-dotted\"> <\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Continuous apixaban is safe and effective in patients undergoing atrial fibrillation ablation at risk of stroke with respect to bleeding, stroke, and cognitive function. Further research is needed to reduce ablation-related acute brain lesions.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-d16ff33e747c1d739410773a294221e5 wp-block-paragraph\" id=\"counter-p\" style=\"text-transform:uppercase\"><strong><strong>PATIENTS<\/strong><\/strong><\/p>\n\n\n\n<div data-aos= \"zoom-in-down\" data-aos-duration=\"400\" data-aos-delay=\"0\" data-aos-easing=\"ease\" data-aos-once=\"true\" class=\"wp-block-uagb-counter uagb-block-9ecbea7b wp-block-uagb-counter--number\" id=\"Studienzahlen\"><div class=\"wp-block-uagb-counter__number\"><span class=\"uagb-counter-block-number\" data-duration=\"1.5\" data-to-value=\"674\" data-from-value=\"0\" data-delimiter=\",\"><\/span><span class=\"uagb-counter-block-suffix\">%<\/span><\/div><div class=\"wp-block-uagb-counter__title\"><\/div><\/div>\n\n\n\n<div class=\"underline-dotted-h-counter\"> <\/div>\n\n\n\n<p class=\"has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-81e95346c680381dde3b53d1060a547e wp-block-paragraph\" id=\"counter-p\" style=\"text-transform:uppercase\"><strong><strong>STUDY sites<\/strong><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-eb6474a77460730965bf3f3c181b9b7d wp-block-paragraph\">in 9 countries<\/p>\n\n\n\n<div data-aos= \"zoom-in-down\" data-aos-duration=\"400\" data-aos-delay=\"0\" data-aos-easing=\"ease\" data-aos-once=\"true\" class=\"wp-block-uagb-counter uagb-block-d59caaa1 wp-block-uagb-counter--number\" id=\"Studienzahlen\"><div class=\"wp-block-uagb-counter__number\"><span class=\"uagb-counter-block-number\" data-duration=\"1.5\" data-to-value=\"49\" data-from-value=\"0\" data-delimiter=\",\"><\/span><span class=\"uagb-counter-block-suffix\">%<\/span><\/div><div class=\"wp-block-uagb-counter__title\"><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-1e42701984e04243472f271b70ee0c13\" style=\"text-transform:uppercase\"><strong>Study duration<\/strong><\/h2>\n\n\n\n<div class=\"studyprocedure-dotted\"> <\/div>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column has-hell-blue-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" id=\"ablauf-schraeg\">\n<h4 class=\"wp-block-heading has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-62cf9e3f7a132b8949978e3c39eca236\"><strong>Start of study<\/strong><\/h4>\n\n\n\n<p class=\"has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-7ca4c8ae643beecb01ddb9a5b5b58f76 wp-block-paragraph\"><strong>2015<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-afnet-gelb-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" id=\"ablauf-schraeg\">\n<h4 class=\"wp-block-heading has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-d07215e91f93b15784880aed59c568a6\"><strong>End of study<\/strong><\/h4>\n\n\n\n<p class=\"has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-8e046dab6efca58909fff9e7b26e456f wp-block-paragraph\"><strong>2017<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" id=\"abstand-weg\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-4bf7a5ff3d027fc2d7c6703dc24b14df\" style=\"text-transform:uppercase\"><strong>Study information for download<\/strong><\/h2>\n\n\n\n<div class=\"studyinformation-dotted\"> <\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"button-unterseiten-hover\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"btn_mitdesign\">\n\t<a download=\"\" href=\"\/wp-content\/uploads\/2024\/11\/AXAFA-study-design.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Study design<\/strong><br>\n\t\t<img decoding=\"async\" class=\"blue-download\" style=\"width: 30px;\" src=\"\/wp-content\/uploads\/2024\/07\/Download-icon-blau.svg\" alt=\"\">\n\t\t<img decoding=\"async\" class=\"white-download\" style=\"width: 30px;\" src=\"\/wp-content\/uploads\/2024\/07\/Download-icon-weiss.svg\" alt=\"\"><\/a>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"btn_mitdesign\">\n\t<a download=\"\" href=\"\/wp-content\/uploads\/2024\/11\/AXAFA-main-result.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Main result<\/strong><br>\n\t\t<img decoding=\"async\" class=\"blue-download\" style=\"width: 30px;\" src=\"\/wp-content\/uploads\/2024\/07\/Download-icon-blau.svg\" alt=\"\">\n\t\t<img decoding=\"async\" class=\"white-download\" style=\"width: 30px;\" src=\"\/wp-content\/uploads\/2024\/07\/Download-icon-weiss.svg\" alt=\"\"><\/a>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" id=\"abstand-weg\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-e98d9d0b2cc4d4920d858a6ae85d9a92\" style=\"text-transform:uppercase\"><strong>Publications<\/strong><\/h2>\n\n\n\n<div class=\"publications-dotted\"> <\/div>\n\n\n\n<p class=\"has-afnet-blau-color has-text-color has-background has-link-color wp-elements-99cd714a6d0c8d024d135859eea6f481 wp-block-paragraph\" style=\"background-color:#dde9f2\">Haeusler KG, Eichner F. A.; Heuschmann P.&nbsp;U.; Fiebach J. B. Engelhorn T, Blank B, Callans D, Elvan A, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Mont L, Cosedis Nielsen J,&nbsp;Piccini JP, Schotten U, Themistoclakis S, Vijgen J, di Biase L, Kirchhof P.&nbsp;<strong>MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.<\/strong>&nbsp; Circulation. 2022;145:906\u2013915. <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.121.056320\" target=\"_blank\" rel=\"noreferrer noopener\">doi:&nbsp;10.1161\/CIRCULATIONAHA.121.056320<\/a>.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs uagb-block-d9eecc0f uagb-tabs__wrap uagb-tabs__hstyle2-desktop uagb-tabs__vstyle6-tablet uagb-tabs__stack1-mobile\" data-tab-active=\"0\" id=\"mehr-anzeigen-studien\"><ul class=\"uagb-tabs__panel uagb-tabs__align-center\" role=\"tablist\"><li class=\"uagb-tab uagb-tabs__active\" role=\"none\"><a href=\"#uagb-tabs__tab0\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"0\" role=\"tab\"><span class=\"uagb-tabs__icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 384 512\"><path d=\"M374.6 310.6l-160 160C208.4 476.9 200.2 480 192 480s-16.38-3.125-22.62-9.375l-160-160c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L160 370.8V64c0-17.69 14.33-31.1 31.1-31.1S224 46.31 224 64v306.8l105.4-105.4c12.5-12.5 32.75-12.5 45.25 0S387.1 298.1 374.6 310.6z\"><\/path><\/svg><\/span><div>Show more<\/div><\/a><\/li><\/ul><div class=\"uagb-tabs__body-wrap\">\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-0\" aria-labelledby=\"uagb-tabs__tab0\" id=\"mehr-anzeigen-studien\">\n<p class=\"has-text-align-left has-afnet-blau-color has-text-color has-background has-link-color wp-elements-6552c9ef4e59a3a3a8be450839b411eb wp-block-paragraph\" style=\"background-color:#dde9f2\">Zink MD, Chua W, Zeemering S, di Biase L, Bayes de Luna A, Callans D, Hindricks G, Haeusler KG, Al-Khalidi HR, Piccini JP, Mont L, Cosedis Nielsen J, Alberto Escobar L, de Bono J, Van Gelder IC, de Potter T, Scherr D, Themistoclakis S, Todd D, Kirchhof P, Schotten U.&nbsp;<strong>Predictors of recurrence of atrial fibrillation within the first 3 months after ablation<\/strong>. EP Europace. euaa132. doi:&nbsp;<a href=\"https:\/\/doi.org\/10.1093\/europace\/euaa132\" target=\"_blank\" rel=\"noreferrer noopener\">10.1093\/europace\/euaa132<\/a>.<\/p>\n\n\n\n<p class=\"has-text-align-left has-afnet-blau-color has-text-color has-background has-link-color wp-elements-140c96c8e1f0a7d4a20c49f63e9af240 wp-block-paragraph\" style=\"background-color:#dde9f2\">Kloosterman M, Chua W, Fabritz L, Al-Khalidi HR, Schotten U, Nielsen JC, Piccini JP, Di Biase L, H\u00e4usler KG, Todd D, Mont L, Van Gelder IC, Kirchhof P. for the AXAFA-AFNET 5 investigators.&nbsp;<strong>Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5<\/strong>. EP Europace. 2020 July; Volume 22; Issue 7; Pages 1026\u20131035.<a href=\"https:\/\/doi.org\/10.1093\/europace\/euaa015\" target=\"_blank\" rel=\"noreferrer noopener\"> doi:&nbsp;10.1093\/europace\/euaa015<\/a>.<\/p>\n\n\n\n<p class=\"has-text-align-left has-afnet-blau-color has-text-color has-background has-link-color wp-elements-176264514e9b854a7fd41f5632adbdf9 wp-block-paragraph\" style=\"background-color:#dde9f2\">Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, N\u00f6lker G, Piccini JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L.&nbsp;<strong>Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation<\/strong>. Eur Heart J. 2018 Aug 21; 39 (32): 2942 &#8211; 2955; 00,1-14.<a href=\"https:\/\/doi.org\/10.1093\/eurheartj\/ehy176\" target=\"_blank\" rel=\"noreferrer noopener\"> doi:&nbsp;10.1093\/eurheartj\/ehy176<\/a>. Epub 2018 Mar 20.<\/p>\n\n\n\n<p class=\"has-text-align-left has-afnet-blau-color has-text-color has-background has-link-color wp-elements-17446dcb04b6d25c75620acffada81e4 wp-block-paragraph\" style=\"background-color:#dde9f2\">Di Biase L, Callans D, Georg Haeusler K, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P.&nbsp;<strong>Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation<\/strong>. Europace. 2017 Jan;19(1):132-138. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28130378\" target=\"_blank\" rel=\"noreferrer noopener\">doi:&nbsp;0.1093\/europace\/euw368<\/a>.&nbsp;Epub 2016 Oct 14<\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" id=\"abstand-weg\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-background\" id=\"studiendesign-block-hacken\" style=\"background-color:#dde9f2\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-203051502688d2654c87f75ea0b1beb0\" style=\"text-transform:uppercase\"><strong>Coordinating Investigator<\/strong><\/h2>\n\n\n\n<div class=\"leader-dotted\"> <\/div>\n\n\n\n<div class=\"wp-block-columns has-background is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"Leitungen\" style=\"background-color:#dde9f2\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\" id=\"kreis\"><img loading=\"lazy\" decoding=\"async\" width=\"520\" height=\"520\" src=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/afnet-Lenkungsausschuss-kreis-Kirchhof-Paulus.png\" alt=\"\" class=\"wp-image-1693\" style=\"object-fit:cover\" srcset=\"https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/afnet-Lenkungsausschuss-kreis-Kirchhof-Paulus.png 520w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/afnet-Lenkungsausschuss-kreis-Kirchhof-Paulus-300x300.png 300w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/afnet-Lenkungsausschuss-kreis-Kirchhof-Paulus-150x150.png 150w, https:\/\/www.af-net.eu\/wp-content\/uploads\/2024\/08\/afnet-Lenkungsausschuss-kreis-Kirchhof-Paulus-500x500.png 500w\" sizes=\"auto, (max-width: 520px) 100vw, 520px\" \/><\/figure>\n<\/div>\n\n\n<h5 class=\"wp-block-heading has-text-align-center has-afnet-blau-color has-text-color has-link-color wp-elements-9bb0d2e762b86614436cb3aa7909a967\"><strong>Prof. Paulus Kirchhof<\/strong><\/h5>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\">Birmingham \/ M\u00fcnster<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" id=\"abstand-weg\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" id=\"infos-studien\">\n<h2 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-a9875f041a7472b8c6e7f51ffec63186\" style=\"text-transform:uppercase\"><strong>Further information<\/strong><\/h2>\n\n\n\n<div class=\"moreinormation-dotted\"> <\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"no-space-studien\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h4 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-096b3beeed4d72132b8124649482a4a6\" style=\"text-transform:uppercase\">Registration<\/h4>\n\n\n\n<p class=\"has-contrast-color has-text-color has-link-color wp-elements-7c780cea4dfa99daff8e9c4732ea1f96 wp-block-paragraph\">EudraCT number: 2014-002442-45<br><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02227550?term=AXAFA&amp;rank=1\" target=\"_blank\" rel=\"noreferrer noopener\">ClinicalTrials.gov: NCT02227550<\/a><br><a href=\"http:\/\/www.controlled-trials.com\/ISRCTN87711003\" target=\"_blank\" rel=\"noreferrer noopener\">ISRCTN: ISRCTN87711003<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-cda1467a0b0f7ee77d04d53ef36ff632\" style=\"text-transform:uppercase\">support<\/h4>\n\n\n\n<p class=\"has-contrast-color has-text-color has-link-color wp-elements-450a5dd7331466e6e02e5e3becc718e4 wp-block-paragraph\"><a href=\"https:\/\/www.bms.com\/de\">Bristol-Myers Squibb<\/a><\/p>\n\n\n\n<p class=\"has-contrast-color has-text-color has-link-color wp-elements-960c8d3a9637f788d927f97adf475809 wp-block-paragraph\"><a href=\"https:\/\/www.pfizer.com\/\">Pfizer<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h4 class=\"wp-block-heading has-afnet-blau-color has-text-color has-link-color wp-elements-83ede75b5083aa32421d6bc43eaba049\" style=\"text-transform:uppercase\">Sponsor<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Kompetenznetz Vorhofflimmern e.V. (Atrial Fibrillation NETwork, AFNET), M\u00fcnster, Germany&nbsp;&nbsp;&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AXAFA-AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy (AXAFA) Study design Investigator-driven, prospective, parallel-group, randomised, open, Blinded Outcome Assessment (PROBE),multi-centre trial to determine the optimal anticoagulation therapy for patients undergoing catheter ablation of atrial fibrillation Inclusion Criteria Non-valvular AF (ECG-documented) with a &#8230; <a title=\"AXAFA\" class=\"read-more\" href=\"https:\/\/www.af-net.eu\/en\/axafa\/\" aria-label=\"Read more about AXAFA\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","iawp_total_views":22,"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":"","_members_access_role":[],"_members_access_error":""},"class_list":["post-11381","page","type-page","status-publish"],"acf":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"timeline-express":false,"timeline-express-thumbnail":false,"1536x1536":false,"2048x2048":false,"vp_sm":false,"vp_md":false,"vp_lg":false,"vp_xl":false,"vp_sm_popup":false,"vp_md_popup":false,"vp_xl_popup":false},"uagb_author_info":{"display_name":"admin","author_link":"https:\/\/www.af-net.eu\/en\/author\/cre8ors\/"},"uagb_comment_info":0,"uagb_excerpt":"AXAFA-AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy (AXAFA) Study design Investigator-driven, prospective, parallel-group, randomised, open, Blinded Outcome Assessment (PROBE),multi-centre trial to determine the optimal anticoagulation therapy for patients undergoing catheter ablation of atrial fibrillation Inclusion Criteria Non-valvular AF (ECG-documented) with a&hellip;","_links":{"self":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/comments?post=11381"}],"version-history":[{"count":15,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11381\/revisions"}],"predecessor-version":[{"id":13254,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11381\/revisions\/13254"}],"wp:attachment":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/media?parent=11381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}